New Delhi: In its boldest move yet, Sun Pharma, India's largest pharmaceutical company, has struck the biggest-ever overseas pharma deal by acquiring US-listed Organon & Co for $11.8 billion (Rs 98,000 crore) in an all-cash transaction.
Strategic Expansion
The deal broadens Sun Pharma's therapeutic breadth and geographic reach in one sweep, adding over 140 high-growth markets including China, along with a portfolio centered on innovative therapies such as women's health, biosimilars, and legacy brands.
Financial Details
Sun Pharma will pay $14 per share, a premium of over 24% to Organon's last closing price on April 24, marking one of the largest M&A deals by an Indian company. On Monday, Sun Pharma shares closed 7% higher at Rs 1,734 on BSE.
Market Position
Once completed, the acquisition will double Sun Pharma's revenue to $12.4 billion and its EBITDA to $3.7 billion, ranking it among the top 25 global pharmaceutical companies. The deal positions Sun Pharma as the top 3 player in women's health, after German firms Merck and Bayer, and the seventh-largest biosimilars company globally.
Organon's Portfolio
Organon, spun off in 2021 from Merck (known as MSD outside the US and Canada), brings a portfolio of over 70 products across women's health, general medicines, and biosimilars, along with six manufacturing facilities worldwide.
Management Commentary
The deal follows Sun Pharma's proven M&A playbook, from the landmark Ranbaxy acquisition in 2014 to a string of in-licensing deals that have strengthened its innovative portfolio and delivered a 14% revenue CAGR between FY10 and FY25. Sun chairman Dilip Shanghvi said: "We are debt-averse, but we are never risk-averse. Biosimilars is a segment where building capabilities organically would take years; Organon gives us that platform immediately."
Analyst View
"Sun Pharma's proposed deal with Organon, valued around 6x EBITDA, appears financially disciplined, supported by steady cash flows," said Vishal Manchanda, analyst at Systematix.
